BioMed X has completed its extrachromosomal DNA (ecDNA) oncology research project with Merck.
The project, which focused on unravelling the mechanisms behind ecDNA formation and propogation — as well as how it impacts cancer cells — launched in August 2022.
Data collected from this project being utilised by Merck for further development of novel therapeutic approaches within precision oncology.
From this research, the team at BioMed X identified genes that may reduce the prevalence of ecDNA in cancer cells.
They also gained a better understanding of how ecDNA localisation affects cancer cell adaptability.
These early findings may offer promising strategies for mitigating cancer heterogeneity and reducing the mechanisms driving therapeutic resistance, potentially improving the efficacy of existing treatments.
Dr Thomas Rückle, Senior Vice President Research at the BioMed X Institute, commented: “Our collaboration with Merck has once again demonstrated the power of combining academic curiosity with industrial expertise."
"The knowledge gained from this project not only advances cancer research but also showcases the potential of ecDNA-targeted therapies. We look forward to continuing our successful partnership with Merck and our joint journey towards a deeper understanding of complex life-threatening diseases.”